Clinical Trial Update: Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating a personalized antisense oligonucleotide targeting CHCHD10 in amyotrophic lateral sclerosis, with enrollment by invitat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Personalized antisense oligonucleotide (CHCHD10)

Snippet

Sponsor: n-Lorem Foundation | Conditions: Amyotrophic Lateral Sclerosis | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION